The Filing Desk

Lineage Cell Therapeutics vs uniQure

Lineage Cell Therapeutics LCTX · uniQure QURE · Biotechnology

uniQure reported revenue of $16 million in fiscal 2025, about the same as Lineage Cell Therapeutics' $15 million in fiscal 2025. Lineage Cell Therapeutics' revenue grew 53.2% in its latest year, and uniQure's fell 40.6%. Lineage Cell Therapeutics had an operating margin of -251.6%, against -1151.4% at uniQure. Free cash flow was −$19 million at Lineage Cell Therapeutics and −$178 million at uniQure.

Side by side

Lineage Cell TherapeuticsuniQure
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$15M$16M
Revenue growth53.2%−40.6%
Revenue growth a year, last 5 years52.0%−15.6%
Gross margin—89.5%
Operating margin−251.6%−1,151.4%
Net margin−436.5%−1,236.0%
Free cash flow−$19M−$178M
Free cash flow margin−133.6%−1,108.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count14.9%18.2%
Last close$0.82$20.23
P/E at the last close——
Insider trades, last 12 monthsbought $878,348, sold $0sold $19.8 million
Piotroski F-score—2 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Lineage Cell TherapeuticsuniQure
Operating margin
Percent of revenue
Lineage Cell TherapeuticsuniQure
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lineage Cell TherapeuticsuniQure

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lineage Cell Therapeutics and uniQure pages.